IMPORTANCE Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor taken once daily, is approved in the United States for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and allows for treatment without chemotherapy. Extended treatment with ibrutinib has demonstrated increased complete response (CR) rates over time.
C hronic lymphocytic leukemia (CLL) follows a heterogeneous clinical course, with many patients experiencing relapse after an initial response to treatment.
1 Complete response (CR) in CLL is associated with improved progression-free and overall survival for some therapies, 1 and several prognostic factors can predict treatment outcomes.
2
Ibrutinib, a first-in-class inhibitor of Bruton tyrosine kinase that is taken once daily, is approved in the United States for the treatment of patients with CLL/small lymphocytic lymphoma (SLL) and allows for treatment without chemotherapy. Extended treatment with ibrutinib leads to an increase in the CR rate over time. [3] [4] [5] In 31 patients with CLL in the first-line setting who received single-agent ibrutinib, the CR rate increased from 13% at primary analysis with a median follow-up of 22.1 months (interquartile range, 18.4-23.2) to 29% with an extended follow-up of approximately 5 years. 5, 6 In 30 patients with relapsed/refractory (R/R) CLL treated with ibrutinib and bendamustine hydrochloride plus rituximab, the CR rate increased from 17% at primary analysis with a median follow-up of 15.8 months to 40% with longer median follow-up of 37 months.
3
In the phase 3 study of bendamustine plus rituximab and ibrutinib in 289 patients with R/R CLL/SLL without del17p, the CR and CRi (CR with incomplete bone marrow recovery) rate with addition of ibrutinib was 33% vs 7.2% with bendamustine plus rituximab alone after a median follow-up of 25 months. 7 The present ad hoc analysis examines baseline factors predictive of CR in patients with CLL/SLL treated with ibrutinib in clinical trials.
Methods
Univariate and multivariate analyses were performed on data from patients with treatment-naive and R/R CLL in studies PCYC-1102 5,8 and PCYC-1112 9 who received single-agent ibrutinib. Participants were followed up in academic and community medical centers in the United States, the United Kingdom, Australia, France, Italy, Ireland, Poland, Spain, and Austria. Participants in PCYC-1102 were enrolled from May 2010 through December 2012 for treatment-naive patients and from May 2010 through August 2011 for patients with relapsed/ refractory disease. 8 The primary objective of PCYC-1102 was safety, and the secondary objectives were preliminary efficacy and long-term safety. Participants in PCYC-1112 were enrolled from June 2012 through April 2013; the primary objective was progression-free survival of ibrutinib compared with ofatumumab by independent review committee. A hematologic response was defined as a platelet count greater than 100 × 10 3 /μL (to convert to ×10 9 /L, multiply by 1.0); absolute neutrophil count greater than 15 × 10 3 /μL (to convert to ×10 9 /L, multiply by 0.001); hemoglobin concentration greater than 11.0 g/dL (to convert to grams per liter, multiply by 10.0); and absolute lymphocyte count less than 4000/μL (to convert to ×10 9 /L, multiply by 0.001), irrespective of nodal or bone marrow response. Patients with CRi (meeting CR criteria except for persistent anemia, thrombocytopenia, or neutropenia) were considered as having a CR for analysis. Complete response was confirmed only if no residual bone marrow disease was present. A logistic regression model of CR rate against each prognostic factor was fit in the univariate model. Statistical analyses performed in this study are all 2-sided. Factors with P < .10 (2-sided) were selected. A multivariate model with these selected factors was simultaneously tested in stepwise selection with an α-to-enter significance level of .1 and an α-toremove significance level of .05. Two-sided P values were derived using the Wald χ 2 test. SAS 9.3 software (SAS Institute Inc) was used for statistical analyses.
Results

Baseline Characteristics
Three hundred twenty-seven ibrutinib-treated patients were evaluated, 31 (9.5%) with CLL in the first-line setting and 296 (90.5%) with R/R CLL. Patients with R/R CLL had received a median of 3 (range, 0-12) previous therapies; 38 patients (11.6%) had 1 previous therapy, 81 patients (24.8%) had 2, and 177 patients (54.1%) had 3 or more previous therapies. 
Efficacy Outcomes
With up to 55.6 months of follow-up and a median time on study of 26.4 months (range, 0.3-55.6 months), the overall population (N = 327) had an ORR of 89.6% from 21 months onward, including 32 patients (9.8%) with CR and a timedependent improvement in rate of CR with continued oncedaily ibrutinib therapy (Table 1 and Figure) . One hundred ninety-one of 327 patients (58.4%) achieved a hematologic response. Median time to first response (including partial response with lymphocytosis) was 2.5 months (range, 0-49.9), whereas median time to CR was 14.7 months (range, 4.6-47.1 months) for those patients achieving CR. Median treatment duration for patients with CR at this long-term follow-up was 35.5 months (range, 13-55 months). At the time of analysis, there were no deaths or disease progression among the 32 patients who achieved CR. The faster time to CR and lower CR rate in PCYC-1112 are likely related to relatively shorter follow-up times, as CR and CRi rates with ibrutinib increase over time.
Univariate and Multivariate Analyses of Prognostic Factors
In the overall patient population by univariate analysis, the odds of achieving CR were significantly increased for patients who at baseline had no bulky disease (lymph node <5 cm vs ≥5 cm), Rai stage 0 to II vs stage III to IV disease, 13 no previous therapy vs 1 or more previous therapies or vs 2 or more previous therapies, and a β2-microglobulin level of 3.5 mg/L or less vs greater than 3.5 mg/L ( Table 2 ). In the patients with R/R disease, univariate analysis showed that bulky disease (lymph node <5 cm vs ≥5 cm), number of previous therapies (0 vs ≥1 or 0 vs ≥2), and β2-microglobulin levels (≤3.5 vs >3.5 mg/L) were baseline factors that had a significant association with the odds of achieving CR.
In the overall patient population, multivariate analysis showed that the odds of achieving a CR increased for patients who had no previous treatment (odds ratio [OR], 2.65; 95% CI, 1.01-6.95; P = .047) and lacked bulky disease (lymph node <5 cm vs ≥5 cm) (OR, 4.97; 95% CI, 1.91-12.91; P = .001; Table 2 ). In patients with R/R disease, multivariate analysis indicated that only having no bulky disease (lymph node <5 cm vs ≥5 cm) (OR, 4.18; 95% CI, 1.68-10.42; P = .002) at baseline was significantly associated with the odds of achieving a CR.
CR Characteristics Across Prognostic Factors
The CR rate was notably higher in patients receiving ibrutinib as their first-line treatment (8 of 31 patients [25.8%]) and those without bulky disease (24 of 142 patients [16.9%]) ( Table 2) . For those patients who were treatment naive and had no bulky disease, the rate of CR was 28.0% (7 of 25 patients). Factors such as del11q, del17p, and unmutated IGHV were not found to be associated with CR.
Discussion
These data show that patients without previous therapy or bulky disease at baseline have a better likelihood of attaining CR to treatment with ibrutinib. Initial responses to ibrutinib were achieved early (median, 2.5 months), with median time to CR of more than 1 year (14.7 months). Ninety percent of patients responded to therapy and demonstrated sustained response, including patients with bulky disease and those who had received previous therapy. With continued once-daily ibrutinib therapy, the depth of response increased, leading to higher CR rates than for those observed in earlier reports. 5, 8, 14 In patients with treatment-naive or R/R CLL, attainment of CR has historically been associated with superior progression-free and overall survival outcomes with chemoimmunotherapy regimens. 15 The achievement of CR with ibrutinib Abbreviations: CLL, chronic lymphocytic leukemia; CR, complete response; ORR, overall response rate; R/R, relapsed/refractory; TN, treatment-naive.
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Complete Response to Ibrutinib in Chronic Lymphocytic Leukemia therapy at the time of this analysis allowed patients to remain in follow-up for a median of 26.4 months with no deaths or disease progression. Owing to the extended time observed to reach CR (Table 1) , the depth of response may improve further. A better understanding of the dynamics and associated clinical attributes of CR may offer an opportunity to explore concepts, such as discontinuation of ibrutinib therapy once a depth of response is achieved.
Conclusions
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